- Home
- AACG vs CMMB Comparison
AACG vs CMMB Comparison
Compare AACG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- CMMB
- Stock Information
- Founded
- AACG 1999
- CMMB 2004
- Country
- AACG China
- CMMB Israel
- Employees
- AACG N/A
- CMMB N/A
- Industry
- AACG Other Consumer Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- CMMB Health Care
- Exchange
- AACG Nasdaq
- CMMB Nasdaq
- Market Cap
- AACG 31.9M
- CMMB 27.0M
- IPO Year
- AACG N/A
- CMMB N/A
- Fundamental
- Price
- AACG $1.01
- CMMB $1.60
- Analyst Decision
- AACG
- CMMB Strong Buy
- Analyst Count
- AACG 0
- CMMB 3
- Target Price
- AACG N/A
- CMMB $7.33
- AVG Volume (30 Days)
- AACG 55.3K
- CMMB 119.1K
- Earning Date
- AACG 11-07-2024
- CMMB 11-14-2024
- Dividend Yield
- AACG N/A
- CMMB N/A
- EPS Growth
- AACG N/A
- CMMB N/A
- EPS
- AACG N/A
- CMMB N/A
- Revenue
- AACG $35,747,843.00
- CMMB N/A
- Revenue This Year
- AACG N/A
- CMMB N/A
- Revenue Next Year
- AACG N/A
- CMMB N/A
- P/E Ratio
- AACG N/A
- CMMB N/A
- Revenue Growth
- AACG 15.80
- CMMB N/A
- 52 Week Low
- AACG $0.50
- CMMB $0.42
- 52 Week High
- AACG $1.65
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- AACG 57.15
- CMMB 52.53
- Support Level
- AACG $0.97
- CMMB $1.54
- Resistance Level
- AACG $1.03
- CMMB $1.73
- Average True Range (ATR)
- AACG 0.05
- CMMB 0.16
- MACD
- AACG -0.01
- CMMB 0.01
- Stochastic Oscillator
- AACG 64.29
- CMMB 45.45
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.